There was no improvement in overall survival with bevacizumab.
Your search for bevacizumab returned 11 results
Outcomes at 2 years comparable among patients with diabetic macular edema receiving aflibercept monotherapy, bevacizumab first
At the end of one year, likelihood of being weaned off treatment was higher for eyes treated with aflibercept versus bevacizumab
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
Pembrolizumab plus chemotherapy with or without bevacizumab could be a new standard of care for first-line therapy in metastatic cervical cancer.
Researchers looked at the use of 6 biosimilars across 38 oncology practices and found that biosimilar use increased from 2019 to 2021.
The approval was based on data from the phase 3 KEYNOTE-826 trial.
Increased recurrence-free survival seen for patients with high-risk HCC following resection or ablation.
Six of 18 indications remain on label for cancer drugs that failed to improve primary end point in trials after receiving accelerated approval
Substantial improvement observed through month 12, which persisted through month 60, but lessened with fewer treatments
- Loading...
